Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity.
Animal research · 2016
- What was studied
- Rat ischemia model and HT-22 cells
- Main finding
- CPG improved selected neurological and locomotor measures after incomplete global ischemia in rats and protected HT-22 cells against glutamate toxicity.
Study data at a glance
- Participants or experimental model
- Rat ischemia model and HT-22 cells
- Reported results
- CPG improved selected neurological and locomotor measures after incomplete global ischemia in rats and protected HT-22 cells against glutamate toxicity.
Study limitations and source details
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Source details
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Abstract reviewed
Sources checked
Citation
Povarnina PY, Kolyasnikova KN, Nikolaev SV, Antipova TA, Gudasheva TA. Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity. Bulletin of experimental biology and medicine
Study source ↗ · DOI 10.1007/s10517-016-3241-5 · Bibliography entry · Link to this summary